Multicenter open-label study to evaluate efficacy of gadobutrolenhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known or suspected CAD by a blinded image analysis

Multicenter open-label study to evaluate efficacy of gadobutrolenhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known or suspected CAD by a blinded image analysis
Recruiting
1 years - 99 years
All
Phase 3
46 participants needed
1 Location

Brief description of study

The primary efficacy objectives of this study are to demonstrate that sensitivity and specificity of gadobutrol-enhanced CMRI exceed prespecified minimum performance thresholds (MPT) of 60% and 55%, respectively and to show superior sensitivity over unenhanced wall motion CMRI at vasodilator rest/stress for the detection of significant coronary artery disease (CAD) in subjects with suspected or known CAD. The study is comparing the diagnostic ability of stress cardiac MRI (CMR) using this contrast agent as compared to coronary angiogram and gated SPECT.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Coronary heart disease, Coronary heart disease, coronary heart disease
  • Age: 1 years - 99 years
  • Gender: All
Updated on 19 Feb 2024. Study ID: 818179

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.